From: Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
Variable | Level | n (%) |
---|---|---|
gender | F | 21 (38.2) |
 | M | 34 (61.8) |
stage | IIIc | 24 (43.6) |
 | IV | 31 (56.4) |
HLA A2 | A2+ | 34 (61.8) |
 | A2- | 21 (38.2) |
dosage | 10 mg/kg | 40 (72.7) |
 | 3 mg/kg | 15 (27.3) |
irAE | N | 31 (56.4) |
 | Y | 24 (43.6) |
Outcome | NED | 35 (63.6) |
 | Relapse | 20 (36.4) |